Skip to main content

Table 3 Effects of adding ezetimibe to rosuvastatin or increasing rosuvastatin dosage on lipid and metabolic outcomes

From: Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

 

Values after 12 weeks

Change after 12 weeks

P Value (Difference Between add on vs. increased dose)

 

Ezetimibe add-on group (n = 21)

Increased rosuvastatin (n = 18)

Ezetimibe add-on group (n = 21)

Increased rosuvastatin (n = 18)

ApoB, g/L

0.89 ± 0.25

0.88 ± 0.22

−0.17 ± 0.18*

−0.13 ± 0.25*

0.53

ApoA1, g/L

1.47 ± 0.26

1.56 ± 0.30

−0.07 ± 0.25

−0.05 ± 0.24

0.15

ApoB:ApoA1

0.55 ± 0.29

0.60 ± 0.23

−0.15 ± 0.29*

−0.12 ± 0.33

0.81

TC, mmol/L

4.23 ± 1.03

4.56 ± 0.75

−1.01 ± 0.79*

−0.50 ± 0.63*

0.03

LDL, mmol/L

2.12 ± 0.63

2.07 ± 0.46

−0.68 ± 0.54*

−0.48 ± 0.55*

0.37

HDL, mmol/L

1.21 ± 0.27

1.31 ± 0.48

−0.00 ± 0.29

0.03 ± 015

0.72

TC:HDL

3.29 ± 1.41

3.73 ± 0.92

−1.63 ± 2.86*

−0.52 ± 0.65*

0.09

TG, mmol/L

1.92 ± 0.98

2.88 ± 1.42

−0.62 ± 0.58*

−0.17 ± 0.57

0.03

AIP

0.16 ± 0.30

0.30 ± 0.38

−0.12 ± 0.20*

−0.03 ± 0.12

0.13

Non-HDL-C, mmol/L

3.06 ± 0.98

3.25 ± 0.71

−0.97 ± 0.68*

−0.53 ± 0.13

0.03

FBG, mmol/L

6.87 ± 2.49

5.82 ± 1.29

0.34 ± 1.28

−0.34 ± 1.75

0.15

hsCRP, mg/L

5.19 ± 7.25

1.72 ± 1.87

−0.60 ± 12.5

−1.06 ± 3.48

0.87

Creatinine, μmol/L

98 ± 58

151 ± 265

8 ± 48

53 ± 258

0.43

ALT, U/L

42 ± 22

34 ± 15

9 ± 17*

1.28 ± 16.6*

0.18

AST, U/L

32 ± 21

29 ± 8

4 ± 14

−0.10 ± 8

0.30

CK, U/L

126 ± 63

189 ± 103

−20 ± 90

12 ± 69

0.23

  1. Data are given as mean (±SD)
  2. *Significant change from their baseline (p < 0.05)
  3. apoB, apolipoprotein B; apoA1,apolipoprotein A1;TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglycerides; API, atherogenic index of plasma; FBG, fasting blood glucose; hsCRP, high-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase